Get startedLog in
    Picture of Tianda Pharmaceuticals logo

    455 — Tianda Pharmaceuticals Cashflow Statement

    0.000.00%
    hk flag iconLast trade - 00:00
    HealthcareHighly SpeculativeMicro CapValue Trap
    Balance sheetIncome statementCashflow
    Subscribe to view all data

    Annual cashflow statement for Tianda Pharmaceuticals, fiscal year end - December 31st, HKD millions except per share, conversion factor applied.

    2022
    March 31st
    2022
    December 31st
    2023
    December 31st
    2024
    December 31st
    2025
    December 31st
    Period Length:12 M9 M12 M12 M12 M
    Source:ARSARSARSARSARS
    Standards:
    HKAS
    HKAS
    HKAS
    HKAS
    HKAS
    Status:FinalFinalFinalFinalFinal
    Net Income/Starting Line-28-47.9-25.7-54.3-69.3
    Depreciation
    Amortisation
    Non-Cash Items-11.36.592.082.4717.5
    Unusual Items
    Other Non-Cash Items
    Changes in Working Capital8.9180-62.53.9427.2
    Change in Accounts Receivable
    Change in Inventories
    Change in Prepaid Expenses
    Change in Accounts Payable
    Change in Other Liabilities
    Other Operating Cash Flow
    Cash from Operating Activities-8.2376.4-49.8-9.714
    Capital Expenditures-46.5-24.4-65.9-42.6-20.6
    Purchase of Fixed Assets
    Purchase / Acquisition of Intangibles
    Other Investing Cash Flow Items13314.8-3.210.80.471
    Sale of Business
    Sale of Fixed Assets
    Sale/Maturity of Investment
    Change in Net Investments
    Purchase of Investments
    Other Investing Cash Flow
    Cash from Investing Activities86.3-9.61-69.1-31.8-20.1
    Financing Cash Flow Items-0.8870.09-25.200.15
    Other Financing Cash Flow
    Total Cash Dividends Paid
    Net Issuance / Retirement of Debt
    Cash from Financing Activities-1.29-28.9-57.4-30.6-15.2
    Foreign Exchange Effects
    Beginning Cash Balance
    Ending Cash Balance
    Net Change in Cash85.86.28-178-76.8-20.9